{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T09:23:25Z","timestamp":1777541005299,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2008,6,12]],"date-time":"2008-06-12T00:00:00Z","timestamp":1213228800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmied Arch Pharmacol"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1007\/s00210-008-0311-x","type":"journal-article","created":{"date-parts":[[2008,6,11]],"date-time":"2008-06-11T07:58:47Z","timestamp":1213171127000},"page":"529-539","source":"Crossref","is-referenced-by-count":51,"title":["Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15"],"prefix":"10.1007","volume":"378","author":[{"given":"Istv\u00e1n","family":"Gyerty\u00e1n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katalin","family":"S\u00e1ghy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judit","family":"Laszy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ottilia","family":"Elekes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Kedves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larisza I.","family":"G\u00e9mesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"P\u00e1sztor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1ria","family":"Z\u00e1jer-Bal\u00e1zs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margit","family":"Kap\u00e1s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c9va","family":"\u00c1gai Csongor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gy\u00f6rgy","family":"Dom\u00e1ny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9la","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsolt","family":"Szombathelyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,6,12]]},"reference":[{"key":"311_CR1","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1073\/pnas.93.5.1945","volume":"93","author":"D Accili","year":"1996","unstructured":"Accili D, Fishburn CS, Drago J, Steiner H, Lachowicz JE, Park BH, Gauda EB, Lee EJ, Cool MH, Sibley DR, Gerfen CR, Westphal H, Fuchs S (1996) A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci USA 93:1945\u20131949","journal-title":"Proc Natl Acad Sci USA"},{"key":"311_CR2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1600-0773.1999.tb01482.x","volume":"84","author":"S Ahlenius","year":"1999","unstructured":"Ahlenius S (1999) Clozapine: dopamine D1 receptor agonism in the prefrontal cortex as the code to decipher a Rosetta stone of antipsychotic drugs. Pharmacol Toxicol 84:193\u2013196","journal-title":"Pharmacol Toxicol"},{"key":"311_CR3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1192\/S0007125000296840","volume":"17","author":"DM Coward","year":"1992","unstructured":"Coward DM (1992) General pharmacology of clozapine. Brit J Psychiatry Suppl 17:5\u201311","journal-title":"Brit J Psychiatry Suppl"},{"key":"311_CR4","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0893-133X(98)00066-9","volume":"20","author":"EV Gurevich","year":"1999","unstructured":"Gurevich EV, Joyce JN (1999) Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons. Neuropsychopharmacology 20:60\u201380","journal-title":"Neuropsychopharmacology"},{"key":"311_CR5","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/01.fbp.0000137857.26150.ab","volume":"15","author":"I Gyerty\u00e1n","year":"2004","unstructured":"Gyerty\u00e1n I, S\u00e1ghy K (2004) Effects of dopamine D3 receptor antagonists on spontaneous and agonist-reduced motor activity in NMRI mice and Wistar rats: comparative study with nafadotride, U 99194A and SB 277011. Behav Pharmacol 15:253\u2013262","journal-title":"Behav Pharmacol"},{"key":"311_CR6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejphar.2007.06.035","volume":"572","author":"I Gyerty\u00e1n","year":"2007","unstructured":"Gyerty\u00e1n I, S\u00e1ghy K (2007) The selective dopamine D3 receptor antagonists, SB 277011-A and S33084 block haloperidol-induced catalepsy in rats. Eur J Pharmacol 572:171\u2013174","journal-title":"Eur J Pharmacol"},{"key":"311_CR7","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0893-133X(01)00312-8","volume":"26","author":"J Ichikawa","year":"2002","unstructured":"Ichikawa J, Dai J, O\u2019Laughlin IA, Fowler WL, Meltzer HY (2002) Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 26:325\u2013339","journal-title":"Neuropsychopharmacology"},{"key":"311_CR8","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0163-7258(01)00139-5","volume":"90","author":"JN Joyce","year":"2001","unstructured":"Joyce JN (2001) Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol Ther 90:231\u2013259","journal-title":"Pharmacol Ther"},{"key":"311_CR9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0014-2999(03)01308-6","volume":"462","author":"HO Kalkman","year":"2003","unstructured":"Kalkman HO, Loetscher E (2003) a2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs. Eur J Pharmacol 462:33\u201340","journal-title":"Eur J Pharmacol"},{"key":"311_CR10","doi-asserted-by":"crossref","unstructured":"Kiss B, Laszlovszky I, Horv\u00e1th A, N\u00e9methy Z, Schmidt \u00c9, Bugovics G, Gyerty\u00e1n I, \u00c1gai-Csongor \u00c9, Dom\u00e1ny G, Szombathelyi Z (2008) Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic activity. I. Neurochemical characterisation of RG-15. Naunyn-Schmiederbergs Arch Pharmacol DOI 10.1007\/s00210-008-0308-5","DOI":"10.1007\/s00210-008-0308-5"},{"key":"311_CR11","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/sj.npp.1300114","volume":"28","author":"LP Lacroix","year":"2003","unstructured":"Lacroix LP, Hows ME, Shah AJ, Hagan JJ, Heidbreder CA (2003) Selective antagonism at dopamine D3 receptors enhances monoaminergic and cholinergic neurotransmission in the rat anterior cingulate cortex. Neuropsychopharmacology 28:839\u2013849","journal-title":"Neuropsychopharmacology"},{"key":"311_CR12","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00213-004-2096-z","volume":"179","author":"J Laszy","year":"2005","unstructured":"Laszy J, Laszlovszky I, Gyerty\u00e1n I (2005) Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats. Psychopharmacology 179:567\u2013575","journal-title":"Psychopharmacology"},{"key":"311_CR13","first-page":"69","volume-title":"Dopamine in the pathophysiology and treatment of schizophrenia. New findings","author":"Y Lecrubier","year":"2003","unstructured":"Lecrubier Y (2003) Amisulpride as a model: clinical effects of a pure dopaminergic agent. In: Kapur S, Lecrubier Y (eds) Dopamine in the pathophysiology and treatment of schizophrenia. New findings. Martin Dunitz, London and New York, pp 69\u201391"},{"key":"311_CR14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0014-2999(02)01602-3","volume":"444","author":"G Marchese","year":"2002","unstructured":"Marchese G, Bartholini F, Ruiu S, Casti P, Saba P, Gessa G, Pani L (2002) Effect of the amisulpride isomers on rat catalepsy. Eur J Pharmacol 444:69\u201374","journal-title":"Eur J Pharmacol"},{"issue":"Suppl B","key":"311_CR15","first-page":"47","volume":"55","author":"HY Meltzer","year":"1994","unstructured":"Meltzer HY (1994) An overview of the mechanism of action of clozapine. J Clin Psychiatry 55[Suppl B]:47\u201352","journal-title":"J Clin Psychiatry"},{"key":"311_CR16","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.pnpbp.2003.09.010","volume":"27","author":"HY Meltzer","year":"2003","unstructured":"Meltzer HY, Li Z, Kaneda Y, Ichikawa J (2003) Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 27:1159\u20131172","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"311_CR17","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1016\/S0014-2999(97)00049-6","volume":"321","author":"MJ Millan","year":"1997","unstructured":"Millan MJ, Gressier H, Brocco M (1997) The dopamine D3 receptor antagonist, (+)-S 14297, blocks the cataleptic properties of haloperidol in rats. Eur J Pharmacol 321:R7\u2013R9","journal-title":"Eur J Pharmacol"},{"key":"311_CR18","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S0022-3565(24)39333-4","volume":"293","author":"MJ Millan","year":"2000","unstructured":"Millan MJ, Dekeyne A, Rivet J-M, Dubuffet T, Lavielle G, Brocco M (2000) S33084, a novel, potent, selective and competitive antagonist at dopamine D3 receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther 293:1063\u20131073","journal-title":"J Pharmacol Exp Ther"},{"key":"311_CR19","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00213-003-1770-x","volume":"174","author":"MJ Millan","year":"2004","unstructured":"Millan MJ, Seguin L, Gobert A, Cussac D, Brocco M (2004) The role of dopamine D3 compared with D2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats. Psychopharmacology (Berl) 174:341\u2013357","journal-title":"Psychopharmacology (Berl)"},{"key":"311_CR20","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/j.1471-4159.2006.04262.x","volume":"100","author":"MJ Millan","year":"2007","unstructured":"Millan MJ, Di Cara B, Dekeyne A, Panayi F, De Groote L, Sicard D, Cistarelli L, Billiras R, Gobert A (2007) Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis. J Neurochem 100:1047\u20131061","journal-title":"J Neurochem"},{"key":"311_CR21","first-page":"545","volume":"262","author":"NA Moore","year":"1992","unstructured":"Moore NA, Tye NC, Axton MS, Risius FC (1992) The behavioral pharmacology of olanzapine, a novel \u201catypical\u201d antipsychotic agent. J Pharmacol Exp Ther 262:545\u2013551","journal-title":"J Pharmacol Exp Ther"},{"key":"311_CR22","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S0893-133X(01)00368-2","volume":"26","author":"T Morimoto","year":"2002","unstructured":"Morimoto T, Hashimoto K, Yasumatsu H, Tanaka H, Fujimura M, Kuriyama M, Kimura K, Takehara S, Yamagami K (2002) Neuropharmacological profile of a novel potential atypical antipsychotic drugY-931 (8-fluoro-12-(4-methylpiperazin-1-yl)- 6H-[1]benzothieno[2,3-b][1,5] benzodiazepine maleate). Neuropsychopharmacology 26:456\u2013467","journal-title":"Neuropsychopharmacology"},{"key":"311_CR23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1192\/S0007125000298309","volume":"168","author":"S Nyberg","year":"1996","unstructured":"Nyberg S, Nakashima Y, Nordstr\u00f6m A-L, Halldin C, Farde L (1996) Positron emission tomography of in vivo binding characteristics of atypical antipsychotic drugs. Review of D2 and 5-HT2 receptor occupancy studies and clinical response. Br J Psychiatry 168:40\u201344","journal-title":"Br J Psychiatry"},{"key":"311_CR24","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0022-3565(24)36394-3","volume":"280","author":"GH Perrault","year":"1997","unstructured":"Perrault GH, Depoortere R, Morel E, Sanger DJ, Scatton B (1997) Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2\/D3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther 280:73\u201382","journal-title":"J Pharmacol Exp Ther"},{"key":"311_CR25","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.pbb.2007.02.019","volume":"86","author":"LM Pritchard","year":"2007","unstructured":"Pritchard LM, Newman AH, McNamara RK, Logue AD, Taylor B, Welge JA, Xu M, Zhang J, Richtand NM (2007) The dopamine D3 receptor antagonist NGB 2904 increases spontaneous and amphetamine-stimulated locomotion. Pharmacol Biochem Behav 86:718\u2013726","journal-title":"Pharmacol Biochem Behav"},{"key":"311_CR26","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/0028-3908(85)90037-1","volume":"24","author":"P Protais","year":"1985","unstructured":"Protais P, Hermier C, Costentin J (1985) The discriminant dopamine antagonist property of benzamides is observed at various times after their systemic or intracerebroventricular administration. Neuropharmacology 24:861\u2013867","journal-title":"Neuropharmacology"},{"key":"311_CR27","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S0022-3565(24)39184-0","volume":"294","author":"C Reavill","year":"2000","unstructured":"Reavill C, Taylor SG, Wood MD, Ashmeade T, Austin NE, Avenell KY, Boyfield I, Branch CL, Cilia J, Coldwell MC, Hadley MS, Hunter AJ, Jeffrey P, Jewitt F, Johnson CN, Jones DN, Medhurst AD, Middlemiss DN, Nash DJ, Riley GJ, Routledge C, Stemp G, Thewlis KM, Trail B, Vong AK, Hagan JJ (2000) Pharmacological actions of a novel, high-affinity, and selective human dopamine D3 receptor antagonist, SB-277011-A. J Pharmacol Exp Ther 294:1154\u20131165","journal-title":"J Pharmacol Exp Ther"},{"key":"311_CR28","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0149-7634(01)00023-9","volume":"25","author":"NM Richtand","year":"2001","unstructured":"Richtand NM, Woods SC, Berger SP, Strakowski SM (2001) D3 dopamine receptor, behavioral sensitization, and psychosis. Neurosci Biobehav Rev 25:427\u2013443","journal-title":"Neurosci Biobehav Rev"},{"key":"311_CR29","first-page":"1239","volume":"275","author":"F Sautel","year":"1995","unstructured":"Sautel F, Griffon N, Sokoloff P, Schwartz J-C, Launay C, Simon P, Costetin J, Schienfelder A, Garrido F, Mann A (1995) Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents. J Pharmacol Exp Ther 275:1239\u20131246","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl 2","key":"311_CR30","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1097\/00004850-199705002-00006","volume":"12","author":"B Scatton","year":"1997","unstructured":"Scatton B, Claustre Y, Cudennec A, Oblin A, Perrault G, Sanger DJ, Schoemaker H (1997) Amisulpride: from animal pharmacology to therapeutic action. Int Clin Psychopharmacol 12[Suppl 2]:S29\u2013S36","journal-title":"Int Clin Psychopharmacol"},{"key":"311_CR31","doi-asserted-by":"crossref","unstructured":"Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, Oblin A, Gonon F, Carter C, Benavides J, Scatton B (1997) Neurochemical characteristics of amisulpride, an atypical dopamine D2\/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 280:83\u201397","DOI":"10.1016\/S0022-3565(24)36395-5"},{"key":"311_CR32","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0165-0173(99)00043-0","volume":"31","author":"JC Schwartz","year":"2000","unstructured":"Schwartz JC, Diaz J, Pilon C, Sokoloff P (2000) Possible implications of the dopamine D3 receptor in schizophrenia and in antipsychotic drug actions. Brain Res Rev 31:77\u2013287","journal-title":"Brain Res Rev"},{"key":"311_CR33","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1566-2772(00)00007-4","volume":"1","author":"P Seeman","year":"2001","unstructured":"Seeman P (2001) Antipsychotic drugs, dopamine receptors and schizophrenia. Clin Neurosci Res 1:53\u201360","journal-title":"Clin Neurosci Res"},{"key":"311_CR34","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0014-2999(97)01235-1","volume":"336","author":"S Sigala","year":"1997","unstructured":"Sigala S, Missale C, Spano P (1997) Opposite effects of dopamine D2 and D3 receptors in learning and memory in the rat. Eur J Pharmacol 336:107\u2013112","journal-title":"Eur J Pharmacol"},{"key":"311_CR35","first-page":"401","volume-title":"Essential psychopharmacology. Neuroscientific basis and practical applications","author":"SM Stahl","year":"2002","unstructured":"Stahl SM (2002) Essential psychopharmacology. Neuroscientific basis and practical applications. 2nd edn. Cambridge University Press, Cambridge","edition":"2"},{"key":"311_CR36","first-page":"1223","volume":"295","author":"GD Stanwood","year":"2000","unstructured":"Stanwood GD, Artymyshyn RP, Kung M-P, Kung HF, Lucki I, McGonigle P (2000) Quantitative autoradiographic mapping of rat brain dopamine D3 binding with [125I]7-OH-PIPAT: evidence for the presence of D3 receptors on dopaminergic and nondopaminergic cell bodies and terminals. J Pharmacol Exp Ther 295:1223\u20131231","journal-title":"J Pharmacol Exp Ther"},{"key":"311_CR37","first-page":"603","volume":"26","author":"G Stille","year":"1971","unstructured":"Stille G, Lauener H, Eichenberger G (1971) The pharmacology of 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]-diazepine (Clozapine). Il Farmaco 26:603\u2013625","journal-title":"Il Farmaco"},{"key":"311_CR38","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/BF00501198","volume":"329","author":"M Vasse","year":"1985","unstructured":"Vasse M, Protais P, Costentin J, Schwartz JC (1985) Unexpected potentiation by discriminant benzamide derivatives of stereotyped behaviours elicited by dopamine agonists in mice. Naunyn Schmiedebergs Arch Pharmacol 329:108\u2013116","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"311_CR39","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0893-133X(01)00261-5","volume":"25","author":"M-L Wadenberg","year":"2001","unstructured":"Wadenberg M-L, Soliman A, VanderSpek SC, Kapur S (2001) Dopamine D2 receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 25:633\u2013641","journal-title":"Neuropsychopharmacology"},{"key":"311_CR40","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/BF01244979","volume":"94","author":"N Waters","year":"1993","unstructured":"Waters N, Svensson K, Haadsma-Svensson SR, Smith MW, Carlsson A (1993) The dopamine D3 receptor: a postsynaptic receptor inhibitory on rat locomotor activity. J Neural Transm Gen Sect 94:11\u201319","journal-title":"J Neural Transm Gen Sect"},{"key":"311_CR41","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00213-004-1940-5","volume":"177","author":"DM Weiner","year":"2004","unstructured":"Weiner DM, Meltzer HY, Veinbergs I, Donohue EM, Spalding TA, Smith TT, Mohell N, Harvey SC, Lameh J, Nash N, Vanover KE, Olsson R, Jayathilake K, Lee M, Levey AI, Hacksell U, Burstein ES, Davis RE, Brann MR (2004) The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology (Berl) 177:207\u2013216","journal-title":"Psychopharmacology (Berl)"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-008-0311-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00210-008-0311-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-008-0311-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T17:30:24Z","timestamp":1738258224000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00210-008-0311-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6,12]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["311"],"URL":"https:\/\/doi.org\/10.1007\/s00210-008-0311-x","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6,12]]}}}